Posted by Michael Wonder on 17 Nov 2024
MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccine for adults and children aged 12 plus
15 November 2024 - The MHRA has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the Omicron JN.1 COVID-19 sub-variant.
Nuvaxovid JN.1, developed by Novavax, is a vaccine licensed for adults and those aged 12 years and older.
